Recent developments in immunotoxin therapy.
Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.
Ghetie
M A
MA
Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas 75235-8576.
Vitetta
E S
ES
D000818:Animals; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000276:immunology; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000922:Immunotoxins